Fourteen patients with Hodgkin's disease resistant to ABVD were treated with MOPP chemotherapy (nitrogen mustard, vincristine, procarbazine, prednisone). Complete remission was obtained in 6 patients (43%). Four of the 6 complete responders are disease free after 5, 20, 23, 35 months. The actuarial median survival after MOPP of all patients is 20 months. These data confirm that there is no «cross-resistance» among the drugs included in the two schedules.
Get full access to this article
View all access options for this article.
References
1.
BerkensonJ., GageR.P.: Survival curve for cancer patients following treatment.J. Am. Stat. Assoc., 47: 581–604, 1952.
2.
De VitaV.T., SimonR.M., HubbardS.M., YoungR.C., BerardC.W., MoxleyJ.H., FreiE., CarboneP.P.: Curability of advanced Hodgkin's disease with chemotherapy.Ann. Intern. Med., 92: 587–595, 1980.
3.
EinhornL.H., WilliamS.D., StevensE.E., BondW.H.: Combination chemotherapy with vinblastine (V), adriamycin (A), bleomycin (B), CCNU (C) and DTIC (D) for MOPP refractory Hodgkin's disease (HD).Proc. ASCO, 1: 167, 1982.
4.
LeviJ.A., WiernikP.A., DiggsC.H.: Combination chemotherapy of advanced previously treated Hodgkin's disease with streptozoticin, CCNU, adriamycin and bleomycin.Med. Ped. Oncol., 3: 33–40, 1977.
5.
LockichJ.J., FreiE., JaffeN., TullisJ.: New multiple agent chemotherapy (B-DOPA) for advanced Hodgkin's disease.Cancer, 38: 667–671, 1978.
6.
LukesR.J., ButlerJ.J.: The pathology and nomenclature of Hodgkin's disease.Cancer Res., 26: 1063–1081, 1966.
7.
PapaG., MandelliF., AnselmoA.P., De LucaA.M., Maurizi EnriciR., MauroF., TestiA.M., AmadoriS., BiaginiC.: Treatment of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD).Eur. J. Cancer Clin. Oncol., 18: 803–806, 1982.
8.
PorzigK.J., PortlockC.S., RobertsonA., RosenbergS.A.: Treatment of advanced Hodgkin's disease with B-CAVE following MOPP failure.Cancer, 41: 1670–1674, 1978.
9.
RappaportH., BerardC.W., ButlerJ.J.: Report of the Committee on Histopatological Criteria, contributing to staging of Hodgkin's disease.Cancer Res., 31: 1864–1865, 1971.
10.
RodgersR.W., GambleJ.F., LohK.K., SchullenbergC.C.: Adriamycin, bleomycin, DTIC, CCNU and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease.Cancer, 46: 2349–2355, 1980.
11.
SantoroA., BonfanteV., BonadonnaG.: Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease.Ann. Intern. Med., 96: 139–142, 1982.
12.
SantoroA., BonadonnaG., BonfanteV., ValagussaP.: Alternating drug combinations in the treatment of advanced Hodgkin's disease.New Engl. J. Med., 306: 770–775, 1982.
13.
StrausD.J., MyersJ., PasseS., YoungC.W., NisceL.Z., LeeB.J., KorinerB., ArlinZ., KempinS., GeeT., ClarksonB.: The eight-drug/radiation therapy program (MOPP/ABVD/RT) for advanced Hodgkin's disease. A follow-up report.Cancer, 46: 233–240, 1980.
14.
VinciguerraV., ColemanM., JarowskiC.I., DegnonT.S., SilverR.T.: A new combination chemotherapy for resistant Hodgkin's disease.JAMA, 237: 33–35, 1977.
